Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals

MT Newswires Live06-18

Merck (MRK) said late Monday that it has received approval from the US Food and Drug Administration for Capvaxive to prevent invasive pneumococcal disease and pneumococcal pneumonia among adults.

Ligand Pharmaceuticals (LGND), a collaborator of Merck's, said Tuesday that the FDA's approval triggers a $2 million milestone payment for Ligand and is entitled to a royalty on worldwide net sales.

"We believe this asset will be an important contributor to our portfolio, which includes more than 25 commercial products including two marketed by Merck," Ligand Chief Executive Todd Davis said in a statement.

Price: 128.56, Change: +1.06, Percent Change: +0.83

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment